Postoperative Pain Management Market, By Pain Type (Acute Pain, Moderate Pain, and Severe Pain), By Product (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Antiepileptic Drugs, COX-2 Inhibitor, Opioids, and Other Analgesics), By Application (Cancer Pain, Arthritic Pain, Neuropathic Pain, Musculoskeletal Pain, and Migraine), By Target Area (Back, Legs, Hand & Arms, and Other), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

[PDF] Postoperative pain treatment aims to reduce postoperative discomfort in patients. Techniques or plans for reducing patients' post-operative pain are referred to as postoperative pain management.

The factors like constant increase in the population, surgical treatments for cancer and rising chronic disorders including chronic obstructive pulmonary disease (COPD) are expected to boost the growth of the Postoperative Pain Management Market. Plastic surgery and cosmetic reconstruction are only two examples of the continually changing lifestyle preferences and choices that have influenced the target market. The continued efforts by various manufacturers to create novel and non-opioid pharmaceuticals product are expected to boost the growth of the Postoperative Pain Management Market.  

Attributes	Details
Postoperative Pain Management Market Value (2022)	US$ 37.1Bn
Postoperative Pain Management Market Projected Value (2032)	US$ 60.4Bn
Postoperative Pain Management Market CAGR (2022 – 2032)	5.0%

Rising Awareness about Surgical Treatments to Fuel Market Growth

The rising awareness about surgical treatments across the globe has become the major factor in the Postoperative Pain Management Market growth. The rising awareness regarding surgical treatments for cancer and other chronic conditions has been driving the growth of the target market.  Furthermore, the changing lifestyle preferences, including increasing preferences for plastic surgeries and aesthetic reconstruction is another key factor leading to the constant rise in the Postoperative Pain Management Market. 

 For instance, in January 2023, The International Society of aesthetic Plastic Surgery (ISAPS) reported its results of its yearly global survey on aesthetic/cosmetic procedures. It showed an overall increase of 19.3 % in the procedures performed by plastic surgeons in 2021 with more than 12.8 million surgical, and 17.5 million non-surgical procedures performed in worldwide, eventually increasing the demand for safe analgesics worldwide.

Growing Prevalence of Chronic Diseases to Fuel Market Growth

The growing prevalence of chronic diseases across the population is one of the key factors contributing to the growth of the Postoperative Pain Management Market. The rise in the acceptance and preferences for reconstructive aesthetic and cosmetic procedures is leading to the increasing demand for novel non-opioid analgesics in postoperative pain management therapy, eventually leading to the increasing growth of the Postoperative Pain Management Market.

For instance, in April 2023, according to (The Hindustan Times) it was reported that there has been an upsurge in the number of people suffering from chronic diseases after the Covid19 pandemic.  Chronic diseases like cancer, diabetes and heart diseases are at a rising level which thereby requires surgical procedures at a higher level and hence leading to the rising demand for safe and non-opiod analgesics (painkillers).

Restrains:

The lack of awareness in patients for appropriate and safe analgesics is the major key factor restraining the growth of the Postoperative Pain Management Market. Majority of the people across the world are familiar with only a selected number of analgesics; such as Paracetamol, NSAIDs (Nonsteroidal anti-inflammatory drugs). Unfortunately, paracetamol and NSAIDs (Nonsteroidal anti-inflammatory drugs), have certain dangerous side effects in case they are used without any proper healthcare guidance, which in turn becomes a barrier to the growth of Postoperative Pain Management Market.

Furthermore, in January 2020, the FDA (Food and Drug Administration) issued a drug safety communication warning for the health care professionals about the risk of adverse effects, like respiratory and breathing problems caused by use of Gabapentinoid, which is a highly prescribed painkiller to treat neuropathic pain.

The Global Postoperative Pain Management Market report segments the market on the basis of Pain Type, Product, Application, Target Area, and Region.

Pain Type Insight

On the basis of Pain Type, Postoperative Pain Management Market is segmented into Acute Pain, Moderate Pain and Severe Pain. The Severe Pain type segment is expected to dominate the growth of the target market at the forecast period, as majority of the procedures and surgeries lead to significant after pain, and hence they are prescribed with effective and strong painkillers. Furthermore, the severe pain type segment held the majority of the market in 2022.

Product Insights

On the basis of Product, Postoperative Pain Management Market is segmented into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Antiepileptic Drugs, COX-2 Inhibitor, Opioids and Other Analgesics. The Non-Steroidal Anti-Inflammatory product segment is expected to dominate the target market growth, as these are widely used all over the world for relieving pain, inflammation and also used to treat high body temperatures. The adoption of strategic efforts by market participants and the rising demand for NSAIDs due to their benefits over other medications, and the rise in surgical operations are the main drivers of the segment's growth.

Application Insights

On the basis of Application, Postoperative Pain Management Market is segmented into Cancer Pain, Arthritic Pain, Neuropathic Pain, Musculoskeletal Pain and Migraine. The Cancer Pain application segment is expected to dominate the growth of the target market as there has been rising prevalence of cancer diseases across the population and hence a rising demand for non-opioid and safe analgesics boost the segment growth.

Target Area Insights

On the basis of Target Area, Postoperative Pain Management Market is segmented into Back, Legs, Hand, Arms and Other.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On the basis of Region, the Postoperative Pain Management Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America region segment is expected to dominate the growth of the target market in the forecast period due to the rising number of surgical operations, increased knowledge of postoperative pain medications, more product approvals, significant technological advancements, rising research & development activities and a greater emphasis on smart healthcare products.

Report Scope:

Attribute	Details
Base year for estimation	2022
Forecast period	2022 – 2032
Market representation	Revenue in USD Billion & CAGR from 2022 to 2032
Market Segmentation	By Pain Type - Acute Pain, Moderate Pain, and Severe Pain. By Product - Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Antiepileptic Drugs, COX-2 Inhibitor, Opioids, and Other Analgesics. By Application - Cancer Pain, Arthritic Pain, Neuropathic Pain, Musculoskeletal Pain, and Migraine. By Target Area - Back, Legs, Hand & Arms, and Other.
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Postoperative Pain Management Market report based on Pain Type, Product, Application, Target Area, and Region.

Postoperative Pain Management Market, By Pain Type:

• Acute Pain
• Moderate Pain
• Severe Pain

Postoperative Pain Management Market, By Product:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
• Antiepileptic Drugs
• COX-2 Inhibitor
• Opioids
• Other Analgesics

Postoperative Pain Management Market, By Application:

• Cancer Pain
• Arthritic Pain
• Neuropathic Pain
• Musculoskeletal Pain
• Migraine

Postoperative Pain Management Market, By Target Area:

• Back
• Legs
• Hand & Arms
• Other

Postoperative Pain Management Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating the Postoperative Pain Management Market includes, Teva Pharmaceutical Industries Ltd., Novartis AG, Allergan plc, Mylan N.V., Pfizer, Inc., Purdue Pharma L.P, Janssen Pharmaceuticals, Inc., Endo International plc, Pacira Pharmaceuticals Inc., Egalet Corporation, and others.

• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
• Allergan plc
• Mylan N.V.
• Pfizer, Inc.
• Purdue Pharma L.P
• Janssen Pharmaceuticals, Inc.
• Endo International plc
• Pacira Pharmaceuticals Inc.
• Egalet Corporation

“*” marked represents similar segmentation in other categories in the respective section

Recent Development:

• In May 2022, the US FDA (Food and Drug Administration) approved an analgesic named “Mounjaro”. It is a non-opioid medication that works by targeting the root cause of the pain, by reducing inflammation, and blocking pain signals. It has been proved as a safe and effective drug to provide significant pain relief for patients suffering from chronic pain and subcutaneously injected in the abdomen, thigh or upper arm.
• In October 2021, the US FDA (Food and Drug Administration) approved a combination pill for the treatment of acute pain in adults which is severe enough to require an opioid analgesic. It is a combination of celecoxib and tramadol (Seglentis).
• In August 2020, the US FDA (Food and Drug Administration) approved an analgesic named “Olinvyk”. It is prescribed as a short-term intravenous use in hospitals and other clinical industries and used for the treatment of acute pain in adults which is severe enough to require an intravenous opioid analgesic.
• In November 2018, the US FDA (Food and Drug Administration) approved a new opioid drug named – “Dsuvia” which has been used for the treatment of acute pain in adults. This drug is only prescribed in highly supervised healthcare settings. It is used sublingually and are particularly used for battlefield injuries and other severe traumas.